A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Noninvasive drug delivery is a promising treatment strategy for ocular posterior segment diseases. Many physiological and anatomical barriers of the eye considerably restrict effective diffusion of therapeutics to the target site. To overcome this problem, a novel cyclic arginine-glycine-aspartate (RGD) hexapeptide and penetratin (PEN) co-modified PEGylation polyamidoamine (PAMAM) was designed as a nanocarriers (NCs), and its penetrating and targeting abilities were evaluated. In this study, we show that PAMAM-PEG (reaction molar ratio 1:32) has a relatively high grafting efficiency and low cytotoxicity. The particle size was within the range of 15–20 nm after modification with RGD and PEN. Cellular uptake of RGD-modified NCs involved significant affinity toward integrin αvβ3, which validated the targeting of neovasculature. An in vitro permeation study indicated that modification with PEN significantly improved penetration of the NCs (1.5 times higher). In vivo ocular distribution studies showed that, the NCs (modified with PEN or co-modified with RGD and PEN) were highly distributed in the cornea and retina (p < .001), and modification extended retinal retention time for more than 12 h. Therefore, these NCs appear to be a promising noninvasive ocular drug delivery system for ocular posterior segment diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 1×
“At present, intravitreal injection of anti-angiogenic antibodies is the first choice for exudative AMD therapy (Heier et al., 2012).”
BackgroundSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 1×
“According to a long-term study (Rofagha et al., 2013), such therapies have improved the prospects of patients with exudative AMD.”
BackgroundAge-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959 · cited 1×
“Previous studies have shown that choroidal neovascularization (CNV) plays a key role in acute visual loss in AMD (Ambati et al., 2003).”
Result
Cited by
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
Javid, H., Oryani, M. A., Rezagholinejad, N., Esparham, A., Tajaldini, M., & Karimi‐Shahri, M. (2024) · Cancer Medicine · doi:10.1002/cam4.6800 · Cited by 277
Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Su, Y., Fan, X., & Pang, Y. (2023) · Biomaterials Science · doi:10.1039/d3bm00505d · Cited by 33
Metadata
- Authors
- Yang, X., Wang, L., Li, L., Han, M., Tang, S., Wang, T., Han, J., He, X., He, X., Wang, A., & Sun, K.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2019-01-01
- Volume
- 26
- Issue
- 1
- Pages
- 989-1001
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2978091066
- Cited by
- 50
- References
- 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. https://app.cochat.ai/papers/10.1080/10717544.2019.1667455
- The paper
- Yang, X., Wang, L., Li, L., Han, M., Tang, S., Wang, T., Han, J., He, X., He, X., Wang, A., & Sun, K. (2019). A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. Drug Delivery. https://doi.org/10.1080/10717544.2019.1667455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.